Newsfeeds - Spark Newswire

1 minute read

Sorrento Therapeutics Reports Mexico Has Executed Contract For Sale Of 5M Of Co.’s COVI-STIX Tests For Mexican Market, No Terms Disclosed

Today, 11:47 AM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, &ldquo, Sorrento&rdquo, )) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with a leading local distributor for the sale and distribution of

SRNE

2 minute read

Sorrento Therapeutics Mexico To Partner With World Boxing Council For Screening Of COVID-19 Of All Convention Attendees with COVI-STIX At The 59th World Boxing Council Convention In Mexico City

By Benzinga Newsdesk

Today, 11:47 AM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))) and the World Boxing Council ("WBC") announced today that Sorrento's COVI-STIX COVID-19 Virus Rapid Antigen Detection Test

SRNE

2 minute read

Sorrento Therapeutics Reports Received Brazilian Health Regulatory Agency Approval For COVISTIX Antigen Test In Brazil

By Benzinga Newsdesk

Today, 11:47 AM

COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil. Commercialization in progress with

SRNE

4 minute read

Sorrento Therapeutics Highlights Results From 2 Phase 2 Studies Of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients

By Benzinga Newsdesk

Today, 11:47 AM

Abivertinib is an oral capsule (100 mg QD or two 50-mg capsules a day) that potentially reduces cytokine storm associated with acute respiratory distress syndrome (ARDS) in severe hospitalized COVID-19

SRNE

1 minute read

FDA
News

Sorrento Announces That COVISTIX Has Received CE Mark And Registration Of Device

By Benzinga Newsdesk

Today, 11:47 AM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced that it has received an official CE Mark for COVISTIX and a Registration Number: BE/CA01/1-17633-00001-IVD. COVISTIX is a sensitive

SRNE

1 minute read

Sorrento Therapeutics Reports Received FDA Clearance To Proceed With Trial For Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors

By Benzinga Newsdesk

Today, 11:47 AM

Anti-TROP-2 ADC with a drug payload SN38 (a DNA polymerase inhibitor) (ESG-401) has received FDA authorization to begin clinical trials in the US. ESG-401 addresses a highly unmet need for the treatment

SRNE

1 minute read

Legal
News

Sorrento Therapeutics Granted U.S. Patent Titled ‘Variant antibodies that bind OX40’

By Benzinga Newsdesk

Today, 11:47 AM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5203&f=G&l=50&d=PTXT&p=105&S1=20211012&OS=20211012&RS=20211012

SRNE

1 minute read

FDA
News

Sorrento Therapeutics Sponsored Study Titled ‘Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer’ Posted To ClinicalTrials.Gov; Study Not Yet Recruiting

By Benzinga Newsdesk

Today, 11:47 AM

https://clinicaltrials.gov/ct2/show/NCT05067257

SRNE

1 minute read

News

Sorrento Therapeutics Files Patent Application Titled ‘Methods for Treating Parkinson’s Disease by Administering Resiniferatoxin’

By Michael Horton

Today, 11:47 AM

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=8135&p=163&f=G&l=50&d=PG01&S1=20210930.PD.&OS=PD/20210930&RS=PD/20210930

SRNE